[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341340-105":59,"doc-detail-341340-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-pharmacoepidemiological-nested-case-control-study-of-risk-factors-for-venous-thromboembolism-with-the-focus-on-diabetes-cancer-socioeconomic-group-medications-and-comorbidities","A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities","","A pharmacoepidemiological nested case-control study evaluates venous thromboembolism (VTE) risk factors in a diabetes-rich population. The analysis includes 299,590 individuals, identifying 3,450 VTE cases and matching 15,875 controls, with data on comorbidities and prescriptions. Multivariable conditional logistic regression estimates adjusted odds ratios. Diabetes, inflammatory bowel disease, and severe psychiatric disorders show strong associations, while several cancers and specific medication classes—especially corticosteroids and gabapentinoids—exhibit elevated VTE risk; lercanidipine is linked to reduced risk.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-pharmacoepidemiological-nested-case-control-study-of-risk-factors-for-venous-thromboembolism-with-the-focus-on-diabetes-cancer-socioeconomic-group-medications-and-comorbidities/341340/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-pharmacoepidemiological-nested-case-control-study-of-risk-factors-for-venous-thromboembolism-with-the-focus-on-diabetes-cancer-socioeconomic-group-medications-and-comorbidities/341340.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What study design and data sources were used to assess VTE risk factors?","Question",{"text":112,"@type":113},"A pharmacoepidemiological nested case-control approach matched 3,450 VTE cases with 15,875 controls and collected information on comorbidities and prescriptions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which non-cancer comorbidities showed the strongest association with VTE?",{"text":117,"@type":113},"Diabetes, inflammatory bowel disease, and severe psychiatric disorders had the strongest associations among non-cancer comorbidities.",{"name":119,"@type":110,"acceptedAnswer":120},"Which medication groups were most strongly associated with VTE, and which drug suggested protection?",{"text":121,"@type":113},"Corticosteroids, gabapentinoids, psychotropic drugs, risedronic acid, and pramipexole were most strongly associated with VTE, while statins and lercanidipine were associated with a lowered risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341340,1790164689,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","| A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities | Diabetes & Vascular Disease Research May-June 2024: 1–13\u003Cbr>© The Author(s) 2024\u003Cbr>Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/14791641241236894](DOI: 10.1177/14791641241236894)\u003Cbr>[journals.sagepub.com/home/dvr](journals.sagepub.com/home/dvr)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Lasse Myllylahti 1 􀀁, Leo Niskanen2,3, Riitta Lassila4,5,6 and Jari Haukka7\u003Cbr>Abstract\u003Cbr>Objectives: A pharmacoepidemiological study to assess VTE risk factors in a diabetes-rich population.\u003Cbr>Methods: The study comprised 299,590 individuals. We observed 3450 VTEs and matched them with 15,875 controls using a nested case-control approach and collected data on comorbidities and prescriptions. By multivariable conditional logistic regression, we calculated ORs with 95%CIs for comorbidities and medications to evaluate their associations with VTE.\u003Cbr>Results: Diabetes (aOR 2.16; 95%CI 1.99–2.34), inﬂammatory bowel disease (1.84; 1.27–2.66), and severe psychiatric disorders (1.72; 1.43–2.05) had the strongest associations among the non-cancer comorbidities. Pancreatic (12.32; 7.11– 21.36), stomach (8.57; 4.07–18.03), lung and bronchus (6.26; 4.16–9.43), and ovarian (6.72; 2.95–15.10) cancers were ranked as high-risk for VTE. Corticosteroids, gabapentinoids, psychotropic drugs, risedronic acid, and pramipexole were most strongly associated (aOR exceeding 1.5) with VTE. Insulin (3.86; 3.33–4.47) and sulphonylureas (2.62; 2.18–3.16) had stronger associations than metformin (1.65; 1.49–1.83) . Statins and lercanidipine (0.78; 0.62–0.98) were associated with a lowered risk of VTE.\u003Cbr>Conclusions: In this cohort, with 50% diabetes prevalence, pancreatic, stomach, lung and bronchus, and ovarian cancers were strongly associated with VTE. Corticosteroids, gabapentinoids, and psychotropic medications had the strongest associations with VTE among medications. This may be valuable for generating hypotheses for the further research. Lercanidipine may be a novel protective medication against VTE.\u003Cbr>Keywords\u003Cbr>Venous thromboembolism, pulmonary embolism, deep vein thrombosis, diabetes, cancer-associated thrombosis, prothrombotic drugs |  |\n| 1 Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland 2Department of Internal Medicine, Pijt-Hme Central Hospital, Lahti, Finland\u003Cbr>3Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland\u003Cbr>4Unit of Coagulation Disorders, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland 5Research Program Unit in Systems Oncology, University of Helsinki, Helsinki, Finland\u003Cbr>6The Finnish Institute of Health and Welfare, Helsinki, Finland\u003Cbr>7Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland\u003Cbr>Corresponding author:\u003Cbr>Lasse Myllylahti, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Haartmaninkatu 4, Helsinki 00290, Finland. Email: lasse.myllylahti@hus.ﬁ |  |\n\nCreative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access pages ([https://us.sagepub.com/](https://us.sagepub.com/)  \nen-us/nam/open-access-at-sage).  \nIntroduction  \nVenous thromboembolism (VTE), with its typical manifestations of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major global health issue, with an incidence of 1–2 per 1000 person-years.1–5 Over time, the understanding of VTE has developed fr","cbCaicLPFwIE14Rr","https://ap.wps.com/l/cbCaicLPFwIE14Rr","pdf",1153689,13,"English","# Abstract\n# Introduction\n## VTE burden and heterogeneity\n## Challenges in predicting VTE risk\n## Non-cancer comorbidities and diabetes","[{\"question\":\"What study design and data sources were used to assess VTE risk factors?\",\"answer\":\"A pharmacoepidemiological nested case-control approach matched 3,450 VTE cases with 15,875 controls and collected information on comorbidities and prescriptions.\"},{\"question\":\"Which non-cancer comorbidities showed the strongest association with VTE?\",\"answer\":\"Diabetes, inflammatory bowel disease, and severe psychiatric disorders had the strongest associations among non-cancer comorbidities.\"},{\"question\":\"Which medication groups were most strongly associated with VTE, and which drug suggested protection?\",\"answer\":\"Corticosteroids, gabapentinoids, psychotropic drugs, risedronic acid, and pramipexole were most strongly associated with VTE, while statins and lercanidipine were associated with a lowered risk.\"}]","A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities | PDF",1790041594,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cf1a39bcef40094eaea83d089ea373a.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b73ff52923ae84b87388baefe2677122.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a19f569bb7d852b57248157f17df25fc.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5399bba9a5de3038d0a1e1e56f2a3a76.webp",980,1306]